KEY FEATURES
| Full Name | Fibroblast Growth Factor 6 |
|---|---|
| Synonym | HBGF6; HST2; HST2 Oncogene; Heparin Secretory-Transforming Protein 2; Heparin-Binding Growth Factor 6 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 7.8-500pg/mL |
| Sensitivity | 3pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human FGF6 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human FGF6. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human FGF6 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human FGF6, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human FGF6. You can calculate the concentration of Human FGF6 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human FGF6 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 23.7 | 44.43 | 248.73 | 23.91 | 47.57 | 245.34 |
| Standard deviation | 1.32 | 2.07 | 8.93 | 1.38 | 2.47 | 13.08 |
| CV(%) | 5.59 | 4.65 | 3.59 | 5.79 | 5.2 | 5.33 |
RECOVERY
The recovery of Human FGF6 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 91-102 | 96 |
| EDTA plasma (n=8) | 90-105 | 96 |
| Cell culture media (n=8) | 93-103 | 98 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human FGF6 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with FGF6 ELISA Kits
| FGFR4 ELISA Kit | publications with FGF6 and FGFR4 |
| FGF1 ELISA Kit | publications with FGF6 and FGF1 |
| FGF3 ELISA Kit | publications with FGF6 and FGF3 |
| FGFR1 ELISA Kit | publications with FGF6 and FGFR1 |
| FGF7 ELISA Kit | publications with FGF6 and FGF7 |
| FGFR2 ELISA Kit | publications with FGF6 and FGFR2 |
| FGF9 ELISA Kit | publications with FGF6 and FGF9 |
| FGF10 ELISA Kit | publications with FGF6 and FGF10 |
| FGFR3 ELISA Kit | publications with FGF6 and FGFR3 |
| FGF23 ELISA Kit | publications with FGF6 and FGF23 |
Pathways associated with FGF6 ELISA Kit
| Activated Point Mutants Of FGFR2 Pathway | Activated Point Mutants Of FGFR2 Pathway |
| Adaptive Immune System Pathway | Adaptive Immune System Pathway |
| Constitutive PI3K/AKT Signaling In Cancer Pathway | Constitutive PI3K/AKT Signaling In Cancer Pathway |
| DAP12 Interactions Pathway | DAP12 Interactions Pathway |
| DAP12 Signaling Pathway | DAP12 Signaling Pathway |
| Disease Pathway | Disease Pathway |
| Downstream Signal Transduction Pathway | Downstream Signal Transduction Pathway |
| Downstream Signaling Events Of B Cell Receptor (BCR) Pathway | Downstream Signaling Events Of B Cell Receptor (BCR) Pathway |
| Downstream Signaling Of Activated FGFR Pathway | Downstream Signaling Of Activated FGFR Pathway |
| FGFR Ligand Binding And Activation Pathway | FGFR Ligand Binding And Activation Pathway |
Diseases associated with FGF6 ELISA Kit
| Hypertrophy | publications with FGF6 and Hypertrophy |
| Cell Transformation, Neoplastic | publications with FGF6 and Cell Transformation, Neoplastic |
| Carcinoma | publications with FGF6 and Carcinoma |
| Breast Neoplasms | publications with FGF6 and Breast Neoplasms |
| Prostatic Diseases | publications with FGF6 and Prostatic Diseases |
| Skin Diseases | publications with FGF6 and Skin Diseases |
| Inflammation | publications with FGF6 and Inflammation |
| Adenocarcinoma | publications with FGF6 and Adenocarcinoma |
| Hyperplasia | publications with FGF6 and Hyperplasia |
| Ovarian Neoplasms | publications with FGF6 and Ovarian Neoplasms |
Organs/Tissues associated with FGF6 ELISA Kit
| Muscle | publications with FGF6 and Muscle |
| Testis | publications with FGF6 and Testis |